The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
1 to 10 of 2173    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Multiple primaries--Heme & Lymphoid Neoplasms: How many primaries are accessioned when a patient is simultaneously diagnosed with systemic mastocytosis and chronic myelomonocytic leukemia (CMML-0) on a single bone marrow biopsy? See Discussion.

Final Jan 17 2020

Solid Tumor Rules (2018)/Multiple primaries--Lung: How are Primary Site and EOD Primary Tumor coded when a patient is diagnosed with four invasive tumors in the right lung that represent three separate primaries, but the not otherwise specified (NOS) tumor and one of the specific subtype/variants are in separate lobes? See Discussion.


Final Jan 09 2020

Histology--Penis: What is the histology code of a glans penis primary with the final diagnosis squamous cell carcinoma, verrucous type? See Discussion.

Final Jan 09 2020

Reportability/In situ--Prostate:  Has there been a change in reportability for prostatic intraepithelial neoplasia (PIN III) (C619)?  The 2018 SEER Manual notes: Collection stopped effective with cases diagnosed 01/01/2001 and later; however, on the casefinding list effective 10/01/2019, code D07.5, carcinoma in situ of prostate, is listed as reportable.

Final Jan 09 2020

Primary site--Breast: how is subsite coded for a breast cancer when it is described as central portion between 1-3:00 or central portion at 12:00?

Final Dec 24 2019

First Course Treatment/Chemotherapy--Colon:  Is maintenance therapy coded as part of the first course of treatment or as part of subsequent course of treatment?

Final Dec 23 2019

Histology--Brain and CNS:  What morphology code should be assigned to a low-grade glial/glioneuronal neoplasm? See Discussion.

Final Dec 23 2019

Histology--Corpus uteri:  Is 8020/3 used for a predominantly dedifferentiated carcinoma with focal well-differentiated endometrioid adenocarcinoma diagnosed in 2018?  See Discussion.

Final Dec 17 2019

Solid Tumor Rules/Multiple primaries--Brain and CNS: What M rule applies to a clinically diagnosed right-sided parietal meningioma undergoing active surveillance, followed by a left-sided frontal anaplastic oligodendroglioma? See Discussion.

Final Dec 16 2019

Solid Tumor Rules (2018)/Multiple primaries--Breast: How many primaries are there and how is histology coded for a breast primary showing encapsulated papillary carcinoma and Paget disease of the nipple? See Discussion.

Final Dec 10 2019
Next 10 >